[ad_1]
The World Health Organization (WHO) has issued a new directive to improve the treatment of multidrug-resistant tuberculosis. The guideline recommended switching to an entirely oral regimen for treating people with MDR-TB.
According to the WHO, this new treatment is more effective and less likely to cause unwanted side effects.
The recommendations are part of a larger set of actions designed to help countries accelerate the pace of progress in the fight against tuberculosis.
It was March 24, every year, on the eve of World Tuberculosis Day.
This year, key partners will gather at WHO in Geneva for the World TB Day symposium to develop a multi-stakeholder and multisectoral collaborative platform to accelerate TB control efforts .
"The theme of this year's World TB Day is: it's time to end TB," said Dr. Tedros Adhanom Ghebreyesus, WHO's Director General. "We stress the urgent need to translate the commitments made at the UN High Level Meeting on TB in 2018 into actions to ensure that all those who need TB care can obtain it."
"This is a set of pragmatic actions that countries can use to accelerate progress and deliver on the high-level commitments made at the first-ever high-level meeting of the United Nations." UN on TB last September, "said Dr. Tereza Kasaeva, Director of the WHO Global Tuberculosis Program.
Since 2000, 54 million lives have been saved and the number of deaths from tuberculosis has been reduced by one third, but 10 million people still suffer from tuberculosis each year, and too many people are deprived of life-saving care .
The WHO recommends strengthening treatment with active drug safety surveillance and providing psychological support to help patients complete their treatment.
The Health Organization also recommends an accountability framework to coordinate actions across sectors and monitor and badyze progress, a dashboard to help countries better understand their own outbreaks through real-time monitoring – switching to electronic TB surveillance systems, a guide to effectively prioritizing the planning and implementation of effective TB interventions based on badyzes of patient pathways to access to care.
Tuberculosis is the leading killer of infectious diseases in the world, killing 4,500 people a day. The heaviest burden is borne by communities facing socio-economic challenges, those who work and live in high-risk environments, the poorest and the most marginalized.
By Jamila Akweley Okertchiri
[ad_2]
Source link
